| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA   |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
The Motley Fool
February 20, 2009
Brian Orelli |
The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit? |
The Motley Fool
February 12, 2010
Brian Orelli |
Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner. |
The Motley Fool
September 20, 2010
Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
June 29, 2010
Brian Orelli |
Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both. |
The Motley Fool
September 30, 2008
Brian Lawler |
Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
April 20, 2010
Brian Orelli |
Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be. |
Pharmaceutical Executive
December 1, 2008
Ron Feemster |
The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond. |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
The Motley Fool
June 9, 2008
Brian Lawler |
Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
July 8, 2011
Brian Orelli |
Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues. |
The Motley Fool
December 12, 2008
Brian Orelli |
Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
June 9, 2011
Brian Orelli |
XOMA Breaks Bad News to Investors XOMA 052 continues to be a disaster in diabetes. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
June 30, 2011
David Williamson |
Biotech Takes On the Next Big Problem The news coming out of this week's annual conference of the American Diabetes Association wasn't good. |
Pharmaceutical Executive
March 1, 2013
Ben Comer |
Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history. |
The Motley Fool
August 23, 2005
Stephen D. Simpson |
A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last? |
The Motley Fool
July 22, 2009
Brian Orelli |
The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough? |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. |
Chemistry World
November 9, 2010
Andrew Turley |
Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
June 11, 2008
Brian Orelli |
Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals. |
The Motley Fool
January 9, 2008
Brian Orelli |
Sirtris' Diabetes Drug: Safe, but Is It Effective? Sirtris has exciting drugs, but is still a pretty risky investment. Investors, this may be one to keep an eye on. |
The Motley Fool
April 15, 2011
Luke Timmerman |
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe? |
The Motley Fool
November 21, 2007
Brian Orelli |
Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note. |
The Motley Fool
September 9, 2008
Brian Orelli |
Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment. |
The Motley Fool
February 4, 2008
Brian Lawler |
Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications. |
The Motley Fool
June 27, 2008
Brian Lawler |
This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide. |
The Motley Fool
November 5, 2007
Brian Lawler |
Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter. |
The Motley Fool
March 31, 2009
Brian Orelli |
Amylin Smacks Down the Competition Amylin's once-weekly blood sugar controlling drug Byetta trounces the competition. |
The Motley Fool
October 22, 2008
Brian Orelli |
Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent. |
The Motley Fool
December 9, 2008
Brian Orelli |
FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
The Motley Fool
November 3, 2009
Brian Orelli |
Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend. |
The Motley Fool
October 20, 2010
Brian Orelli |
There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon. |
The Motley Fool
April 17, 2009
Brian Orelli |
Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half. |
Pharmaceutical Executive
December 1, 2006 |
Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design. |
